|drug309||Convalescent Plasma Wiki||0.39|
|drug293||Colorectal resection Wiki||0.26|
|drug1126||Tele-medicine platform Wiki||0.26|
|drug279||Clinical data Wiki||0.26|
|drug908||Prototype swab Wiki||0.26|
|drug304||Control (albumin 5%) Wiki||0.26|
|drug313||Convalescent Plasma Transfusion Wiki||0.26|
|drug372||Discontinuation of ACEi/ARB Wiki||0.26|
|drug1054||Standard Donor Plasma Wiki||0.26|
|drug999||SLEDD with a L-MOD Wiki||0.26|
|drug299||Continuation of ACEi/ARB Wiki||0.26|
|drug219||COVID-19 exposure Wiki||0.26|
|drug13||1: discontinuation of RAS blocker therapy Wiki||0.26|
|drug307||Control swab Wiki||0.26|
|drug288||Colchicine Tablets Wiki||0.26|
|drug90||Assessment of cardiovascular diseases and cardiovascular risk factors Wiki||0.26|
|drug308||Convalescent COVID 19 Plasma Wiki||0.26|
|drug15||2: No instruction regarding positioning Wiki||0.26|
|drug400||Electrocardiogram, telemetry, echocardiogram, laboratory values Wiki||0.26|
|drug19||2: continuation of RAS blocker therapy Wiki||0.26|
|drug1053||Standard Care Therapy Wiki||0.26|
|drug941||Random Donor Plasma Wiki||0.26|
|drug11||1: Prone positioning Wiki||0.26|
|drug1076||Standard therapy for COVID-19 according to the stablished hospital protocols. Wiki||0.26|
|drug1102||Supportive Care Wiki||0.18|
|drug310||Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki||0.18|
|drug306||Control group Wiki||0.15|
|D002318||Cardiovascular Diseases NIH||1.00|
|D006333||Heart Failure NIH||0.30|
|D054143||Heart Failure, Systolic NIH||0.26|
|D015428||Myocardial Reperfusion Injury NIH||0.26|
|D015427||Reperfusion Injury NIH||0.26|
|D000787||Angina Pectoris NIH||0.26|
|D054058||Acute Coronary Syndrome NIH||0.18|
|D003327||Coronary Disease NIH||0.18|
|D003324||Coronary Artery Disease NIH||0.15|
|D009203||Myocardial Ischemia NIH||0.13|
|D008173||Lung Diseases, Obstructive NIH||0.12|
|D008171||Lung Diseases, NIH||0.11|
|D014947||Wounds and Injuries NIH||0.08|
|D011024||Pneumonia, Viral NIH||0.04|
|D018352||Coronavirus Infections NIH||0.01|
|HP:0001635||Congestive heart failure HPO||0.30|
|HP:0001681||Angina pectoris HPO||0.26|
|HP:0001677||Coronary artery atherosclerosis HPO||0.15|
|HP:0001658||Myocardial infarction HPO||0.13|
|HP:0006536||Obstructive lung disease HPO||0.12|
|HP:0002088||Abnormal lung morphology HPO||0.11|
There are 15 clinical trials
Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.
This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.
Description: The myocardial injury incidence of COVID-19 patientsMeasure: The myocardial injury incidence Time: 75 days
Description: The risk factors analysis for the death of COVID-19 patientsMeasure: The risk factors analysis for the death Time: 75 days
Description: The clinical characteristics description of COVID-19 patientsMeasure: Clinical characteristics Time: 75 days
Description: The clinical course description of COVID-19 patientsMeasure: Clinical course Time: 75 days
Description: The clinical characteristics and prognosis analysis in different cardiovascular comorbidity of COVID-19 patientsMeasure: Cardiovascular comorbidity Time: 75 days
Description: Analysis of causes of death in COVID-19 patientsMeasure: Analysis of causes of death Time: 75 days
It has been reported that nearly half of the patients who are hospitalized for Covid-19 pneumonia have on admission old age or comorbidities. In particular, hypertension was present in 30% of the cases, diabetes in 19%, coronary heart disease in 8% and chronic obstructive lung disease in 3% of the patients. Amazingly, in the two major studies published in the Lancet (Zhou F et al Lancet 2020) and in the New England Journal of Medicine (Guan W et al 2020), the weight of the subjects as well their body mass index (BMI) were omitted. However, obesity, alone or in association with diabetes, can be a major predisposition factor for Covid-19 infection. The primary end-point of our prospective, observational study is to assess the recovery rate in patients with diagnosis of Covid-19 pneumonia. Among the other secondary end-points, we intend to find the predictors of the time to clinical improvement or hospital discharge in patients affected by Covid-19 pneumonia.
Description: mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.Measure: rate of recovery Time: 3 weeks
Description: comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complicationsMeasure: time to improvement Time: 3 weeks
Description: the efficacy of different pharmaceutical treatment against Covid-19Measure: efficacy of treatments Time: 3 weeks
Description: liver, kidney or multiorgan failure, cardiac failureMeasure: organ failure Time: 3 weeks
CAPACITY (www.capacity-covid.eu) is a registry of patients with COVID-19 across Europe and has been established to answer questions on the role of cardiovascular disease in this pandemic. It is an extension of the Case Record Form (CRF) that was released by the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) and WHO (World Health Organisation) in response to the emerging outbreak of COVID-19.
Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.
Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social contextMeasure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients Time: 6 months
Description: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);Measure: Number of patients included in this platform Time: 6 months
Description: Will be the number of sessions per patient multiplied with the number of patients includedMeasure: Number of consultations/sessions given Time: 6 months
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.
Description: mortality of any causeMeasure: All-cause mortality Time: During 1 year follow-up
Description: mortality of any causeMeasure: 30-day mortality Time: Within 30 days after inclusion
Description: Myocardial infarction, stroke, or CV deathMeasure: Major adverse cardiovascular events Time: During 1 year follow-up
Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19. Individuals with a history of cardiovascular disease develop a more severe illness and have higher rates of death. Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of infection, there are ongoing scientific discussions on whether they should be stopped or continued in patients with COVID-19. It is crucial to determine whether RAS blockers should be discontinued or not in patients with COVID-19.
Multicentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.
Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 months
Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 months
Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severityMeasure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity Time: 3 months
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first reports of COVID-19 came from Wuhan, China in December of 2019. Since then, the disease has spread rapidly around the globe, accounting for thousands of deaths in multiple countries. On March 11th, 2020, the World Health Organization declared COVID-19 as a pandemic. Although COVID-19 manifests primarily as a respiratory illness, several cardiovascular implications have been reported related to its natural course and treatment. Its exact effect on the cardiovascular system though is currently unknown. Therefore, we propose a retrospective, observational, case-control study looking for cardiovascular manifestations of COVID-19, including laboratory evidence of myocardial injury, electrocardiographic changes, arrhythmias and echocardiographic abnormalities. Hospitalized patients admitted with fever, cough, sore throat, and/or dyspnea who were tested positive for SARS-CoV-2 will be included in our study and will be matched based on their age and gender with patients admitted with similar symptoms who tested negative for SARS-CoV-2. The electronic medical charts of the study subjects will be reviewed and relevant demographic, clinical, laboratory and imaging findings will be deidentified and recorded. Since our study will be a retrospective chart review study it carries minimal risk for the patients and the investigators. Cardiovascular disease associated with COVID-19 might be contributing to the high mortality rates and its recognition will allow for prevention, early diagnosis and appropriate treatment. This will be the first, large, case-control study assessing cardiovascular involvement of COVID-19 in a well-defined cohort of patients.
COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.
Description: T-cell immunophenotypeMeasure: T-cell immunophenotype Time: 12 months from enrollment
Description: death, survival to dischargeMeasure: Mortality Time: 12 months from enrolment
Description: Admission to the intensive careMeasure: ITU admission Time: 12 months from enrolment
Description: Defined by troponin rise to >99th centileMeasure: Myocardial injury Time: 12 months from enrolment
Patients presenting with the coronavirus-2019 disease (COVID-19) have a very high risk of cardiovascular adverse events, including death from cardiovascular causes. Unfortunately, there are no reliable statistics on the frequency and severity of these complications during the index hospitalization. Moreover, the long-term cardiovascular outcomes of these patients are entirely unknown. The investigators aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and determine their long-term cardiovascular outcomes.
Description: Cardiovascular mortality is defined according to the Academic Research Consortium-2 and will be independently adjudicated by a Clinical Events Committee.Measure: Cardiovascular mortality Time: 1-year
Description: Acute myocardial infarction is defined according to the Academic Research Consortium-2.Measure: Acute myocardial infarction Time: 1-year
Description: Stroke is defined according to the Academic Research Consortium-2.Measure: Stroke Time: 1-year
Description: Documented hospital admission due to heart failureMeasure: Heart failure hospitalization Time: 1-year
Description: Documented by a chest computed tomographyMeasure: Pulmonary embolism Time: 1-year
Description: Documented hospital admission due to any cardiac arrhythmiaMeasure: Cardiac arrhythmias Time: 1-year
Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.
Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, strokeMeasure: Adverse events Time: through study completion, an average of 2 weeks
Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpointsMeasure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: through study completion, an average of 2 weeks
Description: Ventilation during hospitalizationMeasure: Ventilation during hospitalization Time: through study completion, an average of 2 weeks
Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpointsMeasure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: prolonged follow up, through study completion, an average of one year
The coronavirus disease 2019 (COVID-19) global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused considerable morbidity and mortality in over 170 countries. Increasing age and burden of cardiovascular comorbidities are associated with a worse prognosis among patients with COVID-19. In addition, serologic markers of more severe disease including coagulation abnormalities and thrombocytopenia, are not uncommon among patients hospitalized with severe COVID-19 infection and are more common in patients who died in-hospital. As the COVID-19 pandemic continues to grow, there is a pressing need to identify safe, effective, and widely available therapies that can be scaled and rapidly incorporated into clinical practice. Understanding the putative mechanism of increased mortality risk associated with abnormal coagulation function and cardiac injury is critical to guide studies of promising therapeutic interventions. Published and anecdotal reports indicate that endothelial dysfunction and thrombosis are common in critically ill patients with COVID-19, including reports of diffuse microvascular thrombosis in the lungs, heart, liver, and kidneys. Patients with cardiovascular disease (CVD) and CVD risk factors are known to have endothelial dysfunction and a heightened risk of thrombosis. A recent study of COVID-19 inpatients from Wuhan, China observed that an elevated D-dimer level greater than 1 ug/mL was associated with an 18 times higher risk of in-hospital death, underscoring the importance of increased coagulation activity as a potential modifiable risk marker that may drive end-organ injury. Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease, and the association between coagulopathy and adverse outcomes in patients with sepsis, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy and safety.
Description: Aim 1 - Risk of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.Measure: Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock. Time: 12 weeks
Description: Aim 2 - Risk of major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.Measure: Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition. Time: 12 weeks
Background: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease. Aim: The purpose of the study is to characterise the clinical course of adult inpatients with COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry. Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. The principal investigator provides dedicated electronic case report form. The primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.
Description: All-cause and cardiovascular mortality during index hospitalization.Measure: In-hospital mortality. Time: Hospitalization period, assessed up to 30 days
Description: The duration of hospitalization on the intensive care unit.Measure: The length of stay in the intensive care unit. Time: Hospitalization period in the ICU, assessed up to 30 days
Description: The total length of stay in the hospital.Measure: The duration of hospitalization. Time: Hospitalization period, assessed up to 30 days
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.
Description: Number of death during hospitalizationMeasure: Number of In-Hospital Death Time: During hospitalization, average 2-3 weeks
Description: Length of stay in the hospitalMeasure: Length of Stay Time: During hospitalization, average 2-3 weeks
Description: Successful treatment will be defined by two consecutive negative tests for COVID-19Measure: Number of Successful Treatment Time: During hospitalization, average 2-3 weeks